Our Mission: Launching & growing new Israeli biotech companies developing innovative protein-based biotherapeutics from early stage to late-clinical phase

1. May 2017
Bio-XL
Home for BioPharmaceutical Startups
Deal-flow
Bio-XL Contact: Ouri Fischel, Director of Bus. Dev.
Hidekel 19 POB 13240, Yavne ofischel@gmail.com
Israel +972 (0)54 432-7476

2. Bio-XL Mission
Launching & growing new Israeli biotech
companies developing innovative protein-
based biotherapeutics from early stage to
late-clinical phase

3. Who we are ?
• Team of highly committed professionals with many years of hands-
on and management experience in the biopharma industry – from
early stage to clinical phase.
• We have experience in:
 Validation of innovative project/technology in compliance with pharma
industrial standards.
 Entrepreneurship – foundation and management of startup companies.
 Regulatory affairs – FDA and EMA.
• We collaborate with the major players involved in drug discovery &
development.

4. The Founding Team
Meir Azulay, MSc – Managing Director
Meir Azulay has several decades of experience in process development and manufacturing of
biopharmaceutical drugs in Merck-Serono (participated in development and manufacturing of Rebif, blockbuster
for MS). MSc in biochemistry from the Hebrew University in Jerusalem.
Since 2005 is founder and CEO of CDMO company as well as several start-up companies. Meir Azulay is CEO and
share holder in BioPharm labs (BPL).
Avraham Laban, PhD – CTO & Portfolio Manager
Dr. Avraham Laban has vast experience in drug development, enzyme production and biochemical analysis.
Avraham held research and teaching positions at prestigious institutions across the United States and Israel.
Avraham is engaged in founding startup companies in the fields of Renewable Energy and “Green chemistry” and
is signed on several patents for novel technologies. In recent years Avraham is the CTO of BPL, engaged in process
development of proteins used in early stage technologies of biopharmaceutical drug candidates.
Ouri Fischel, PhD MBA – Investor relations & Bus. Dev.
Ouri is a business developer with substantial experience in drug discovery. He has been involved with protein
kinase inhibitors design for cancer treatment in collaboration with Sanofi-Aventis and Janssen Pharmaceutica
(J&J). With PhD studies in pharmacology and MBA in biomedical management, he has acquired the necessary
skills and experience in entrepreneurship and investment banking. Ouri has successfully raised funding for
companies involved in Rational Drug Design, Cheminformatics and Machine Learning.

5. Biologics development challenges
• Production (Expression, Cost-effectiveness, Regulatory
approvable)
• Purification (Multi-step, Viral inactivation & Removal,
Contaminants Separation)
• Analytics (3D and Primary Structure, Characterization)
• Formulation (Stability, Protein PK/PD, Bioactivity)
• Scalability





Bio-XL

6. Bio-XL advantages
• Fully equipped biological lab enabling small to pilot scale
experimental work
• Network of service providers in all relevant fields for early
stage biopharma startup
• Network of investing funds (Israeli and global)
• BioPharma startups HUB
• Ecosystem location (Tel Aviv, Weizmann Inst., Hadassah,
Hebrew Univ., Technion)





Bio-XL

7. Success stories
• Non-stable non-active fusion protein expressed in E.coli
 Customer: Start up company.
 Result: Company closed down following our findings
• Non-accurate data on fusion recombinant protein
Study showed that the structure of protein is different from reported by inventor (resulting from different
plasmid sequence as thought to be), having impact on bioactivity.
 Customer: Project within incubator.
 Result: Project discontinued following our findings; returned to inventor
• Increase of productivity made product economically feasible
Increase of yield in E.coli 2000 fold; purification process and analytical tests development
 Customer: US-based Start up company
 Result: Tech. transferred to company’s facility (in US)
• Successful extraction of active protein from plant made product technologically feasible
Development of extraction process followed by purification and testing methods.
 Customer: Start up company grown from incubator
 Result: Company received further financing. Currently in clinical trials
Bio-XL
 Validation
 Validation
 Production
 Process
Development

8. Bio-XL Operation & Principles
Selection &
Licensing
•Scouting followed by careful selection of early stage technologies
•Licensing agreement with TTOs and Entrepreneurs
Fund
Raising
•Fund raising from reliable and robust investors for each technology
NewCo
Setup
•Establishment of New Company (NewCo)
•Obtaining lab and office space in Bio-XL facility
Validation
•6-12 months program to assess and improve critical issues:
•Molecule Characterization, mechanism of action in-vitro and in-vivo; IP

9. Bio-XL Operation & Principles (Cont.)
NewCo
Corporate
•NewCo establishes management, board of directors and SAB
Operation
•NewCo independently decides either to do work in-house or sub-contract
Funding
•NewCo independently deploys its funding strategy to reach its goals
Bio-XL
•Bio-XL operates as facilitator and mentor to provide NewCo with all means
allowing smooth and fast progress

10. Bio-XL Capabilities
• Contract Development & Manufacturing Organization (CDMO) to Israeli and
worldwide biotech, with 12 years experience and more than 200 different
projects in various scopes and scales
• Capabilities include:
 Clone development and expression in mammalian, bacterial and yeast cell lines
 Upstream process development, scale up and production (up to 20L fermentor, 5L
bioreactors)
 Purification and API formulation development and production at gram scales
 Analytical methods development to support process development and release API
 Molecule characterization enabled
 Animal studies enabled
 Supply pre-clinical studies
 GMP production to supply clinical studies enabled
• Bio-XL facility – offices and labs (500m2), located in Yavne industrial zone, Israel

11. • Bio-XL uses strict methodologies for evaluation of deal-flow
candidates, evaluating market-ability, uniqueness & innovation and
regulatory adequacy.
• Presently, Bio-XL scouting focuses mainly on cancer therapy and
protein stabilization technologies.
• Bio-XL is currently raising funds for its deal flow technologies.
• Current round aims at raising sufficient funding to reach early
clinical stage.
• Bio-XL plans to leverage investment by matching it with non-diluting
funding.
Bio-XL significantly increases
success potential
Deal Flow

12. Bio-XL
Home for BioPharmaceutical Startups